Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
CIGB Sancti Spíritus is a specialized Cuban biotechnology center focused on the development and industrial production of monoclonal antibodies, recombinant proteins, and diagnostic reagents. As a key unit of the Center for Genetic Engineering and Biotechnology (CIGB) within the BioCubaFarma group, it provides essential components for national healthcare programs, including the HeberFast Line of pregnancy tests. The center plays a vital role in the production of reagents for flagship Cuban products such as the Abdala COVID-19 vaccine and the therapeutic Heberprot-P. Its facilities are equipped for high-purity protein purification and the generation of biological tools used in clinical diagnostics. The institution serves both the domestic market and international partners through Cuba's state-led biotechnology export initiatives.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on CIGB Sancti Spíritus.